⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIOA News
BioAge Labs, Inc. Common Stock
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
globenewswire.com
BIOA
BioAge Announces Proposed Public Offering
globenewswire.com
BIOA
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
globenewswire.com
BIOA
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
globenewswire.com
BIOA
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
globenewswire.com
BIOA
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
BIOA
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
globenewswire.com
BIOA
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
prnewswire.com
BIOA